Gelesis, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-02-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.gelesis.com
Study on GS300 on NAFLD
Not Applicable
- Conditions
- Weight LossNonalcoholic Fatty Liver
- Interventions
- Device: PlaceboDevice: GS300
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04887766
Assessing GS500 in Functional Constipation
Not Applicable
- Conditions
- Constipation - Functional
- Interventions
- Device: PlaceboDevice: GS500
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT04887896
Effects of Gelesis200 on Appetite Parameters, Food Intake, and Glycemic Control in Overweight or Obese Prediabetic Subjects: A Sub-Study of LIGHT-UP
Not Applicable
Completed
- Conditions
- PreDiabetesType2 DiabetesOverweight and Obesity
- Interventions
- Device: Gelesis200Device: PlaceboDevice: Gelesis200 and Placebo
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03622424
- Locations
- 🇩🇰
University of Copenhagan, Frederiksberg, Denmark
Gelesis Glycemic Index Study
Not Applicable
Completed
- Conditions
- PreDiabetesObesityDiabetes
- Interventions
- Device: Gelesis200Other: Water, only (placebo)
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03124134
- Locations
- 🇨🇦
inVentiv Health Clinique, Quebec City, Canada
Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes
Not Applicable
- Conditions
- PreDiabetesObesityOverweightDiabetes
- Interventions
- Device: Gelesis200Device: Placebo
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT03058029
- Locations
- 🇺🇸
Metabolic Research Institute, Inc., West Palm Beach, Florida, United States
🇨🇦University of Ottawa - Institut de Recherche de l'Hospital d'Ottawa (IRHO) (Ottawa Hospital Research Institute (OHRI)), Ottawa, Ontario, Canada
🇺🇸Tarheel Clinical Research, LLC, Sugar Land, Texas, United States
Extension Study of Gelesis100 on Body Weight
Not Applicable
Completed
- Conditions
- Overweight and Obesity
- Interventions
- Device: Gelesis100 (2.25 g)
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03021291
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Clinical Trial Investigators, Tustin, California, United States
🇺🇸Arternis Institute for Clinical Research, San Diego, California, United States
Effect of GSP3 on Body Weight in Overweight and Obese Subjects
Not Applicable
Completed
- Conditions
- OverweightObesity
- Interventions
- Device: GSP3Dietary Supplement: Avicel (modified Cellulose)
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT03008954
- Locations
- 🇮🇹
Policlinico Umberto I, Rome, Italy
🇨🇿Hradec Králové, Hradec, Czechia
🇮🇹Federico University Hospital, Naples, Italy
Gelesis200 Safety and Tolerability Study and Effects on Glycemic and Appetite Parameters
Not Applicable
Completed
- Conditions
- Healthy Overweight Obese
- Interventions
- Device: Gelesis200Other: Placebo
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02652962
The Effect of Gelesis100 on the Pharmacokinetics of Metformin
Not Applicable
Completed
- Conditions
- Healthy Overweight Obese
- Interventions
- Device: Gelesis100Drug: Metformin
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02524821
A Scintigraphic Study to Investigate the Effect of Gelesis100 on Gastric Emptying in Overweight and Obese Subjects
Not Applicable
Completed
- Conditions
- OverweightObesity
- Interventions
- Other: PlaceboDevice: Gelesis100
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2016-08-23
- Lead Sponsor
- Gelesis, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02487602
- Locations
- 🇬🇧
Bio-Images Research Ltd, Glasgow, Scotland, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath